
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Development Success for Dapagliflozinum 10 mg
Details : Dapagliflozinum, a miscellaneous product targeting SGLT2, shows promise in treating undisclosed key focus area.
Product Name : Dapagliflozinum-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 23, 2025
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
